News

Bayer's asundexian becomes world's first approved Factor XIa inhibitor, cleared in China for stroke prevention

What's the deal? China's National Medical Products Administration (NMPA) has approved Bayer's asundexian, to be sold under the brand name Sunharbo, for adults who have had a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack (a brief "mini-stroke") and need to lower their risk of another stroke. The decision on 26 October 2026 followed a priority review and makes asundexian the first Factor XIa inhibitor approved anywhere in the world.

Why it matters: Asundexian is a once-daily oral pill that blocks Factor XIa, a protein involved in blood clotting, aiming to prevent stroke-causing clots with less bleeding risk than older blood thinners. The approval is based on the global phase 3 OCEANIC-STROKE trial, which randomised more than 12,000 patients and showed that asundexian added to antiplatelet therapy cut the risk of recurrent ischemic stroke by 26% versus antiplatelet therapy alone. Stroke is the leading cause of death and disability in China, and asundexian is the first medicine in its class available there; Bayer is still in talks with regulators in other regions.

Read more: Bayer, 26 October 2026

More top stories